 Connection
Christopher Lieu to Neoplasm Staging
This is a "connection" page, showing publications Christopher Lieu has written about Neoplasm Staging.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.716 |
|
|
|
-
Lieu CH, Golemis EA, Serebriiskii IG, Newberg J, Hemmerich A, Connelly C, Messersmith WA, Eng C, Eckhardt SG, Frampton G, Cooke M, Meyer JE. Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. Clin Cancer Res. 2019 10 01; 25(19):5852-5858.
Score: 0.128
-
Lieu CH, Corcoran RB, Overman MJ. Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:207-215.
Score: 0.128
-
Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ru?z-Garc?a E, You YN, Baxter N. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 06 01; 37(16):1436-1447.
Score: 0.127
-
Lieu CH, Hidalgo M, Berlin JD, Ko AH, Cervantes A, LoRusso P, Gerber DE, Eder JP, Eckhardt SG, Kapp AV, Tsuhako A, McCall B, Pirzkall A, Uyei A, Tabernero J. A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. Oncologist. 2017 09; 22(9):1024-e89.
Score: 0.111
-
Lai SH, Vogel JD, Vemuru S, Messersmith W, Lieu C, McCarter MD, Birnbaum E, Chapman BC. Improved Survival After Adjuvant Therapy in Locally Advanced Rectal Cancer Patients With Pathologic Complete Response. Dis Colon Rectum. 2023 07 01; 66(7):983-993.
Score: 0.041
-
Chapman BC, Lai SH, Friedrich T, Lieu CH, Moskalenko M, Olsen JR, Herter W, Birnbaum EH, McCarter MD, Vogel JD. Rectal Cancer: Clinical and Molecular Predictors of a Complete Response to Total Neoadjuvant Therapy. Dis Colon Rectum. 2023 04 01; 66(4):521-530.
Score: 0.038
-
Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022 03 10; 40(8):892-910.
Score: 0.038
-
Stumpf PK, Amini A, Jones BL, Koshy M, Sher DJ, Lieu CH, Schefter TE, Goodman KA, Rusthoven CG. Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. Cancer. 2017 Sep 01; 123(17):3402-3409.
Score: 0.028
-
Meguid C, Schulick RD, Schefter TE, Lieu CH, Boniface M, Williams N, Vogel JD, Gajdos C, McCarter M, Edil BH. The Multidisciplinary Approach to GI Cancer Results in Change of Diagnosis and Management of Patients. Multidisciplinary Care Impacts Diagnosis and Management of Patients. Ann Surg Oncol. 2016 11; 23(12):3986-3990.
Score: 0.026
-
Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, Diamond JR, de Vries EG, Verheul HM, Lieu CH, Kim GP, Wang Y, Scales SJ, Samineni D, Brunstein F, Choi Y, Maslyar DJ, Colon-Otero G. Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2016 Mar; 15(3):439-47.
Score: 0.025
-
Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs. 2016 Apr; 34(2):176-83.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|